Avanos Medical (AVNS) Depreciation & Amortization (CF) (2013 - 2026)

Avanos Medical's Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $10.2 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 6.25% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $39.5 million (down 9.61% YoY), while the FY2025 annual figure was $38.9 million, down 14.51% from the prior year.
• Depreciation & Amortization (CF) came in at $10.2 million for Q1 2026 at Avanos Medical, up from $9.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $13.4 million in Q4 2022 to a low of $9.4 million in Q3 2025.
• A 5-year average of $11.1 million and a median of $11.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) soared 41.05% in 2022 and slipped 19.66% in 2025, its largest moves.
• Avanos Medical's Depreciation & Amortization (CF) stood at $13.4 million in 2022, then dropped by 14.18% to $11.5 million in 2023, then fell by 3.48% to $11.1 million in 2024, then declined by 10.81% to $9.9 million in 2025, then rose by 3.03% to $10.2 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $10.2 million, $9.9 million, and $9.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison